Short Interest in Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) Rises By 76.8%

Cipher Pharmaceuticals Inc. (OTCMKTS:CPHRF) (TSE:CPH) was the recipient of a significant growth in short interest during the month of September. As of September 30th, there was short interest totalling 63,100 shares, a growth of 76.8% from the September 15th total of 35,700 shares. Based on an average daily trading volume, of 98,600 shares, the days-to-cover ratio is presently 0.6 days.

Cipher Pharmaceuticals Price Performance

Shares of CPHRF traded up $0.31 during mid-day trading on Friday, hitting $12.94. 25,257 shares of the company’s stock were exchanged, compared to its average volume of 22,169. Cipher Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $14.60. The business’s 50 day moving average is $11.65 and its two-hundred day moving average is $8.28.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.